Search

ADMA Biologics Inc

Abierto

SectorSanidad

9.47 0.64

Resumen

Variación precio

24h

Actual

Mínimo

9.23

Máximo

9.52

Métricas clave

By Trading Economics

Ingresos

-7.5M

38M

Ventas

9.9M

124M

P/B

Media del Sector

13.929

57.002

BPA

0.16

Margen de beneficios

30.405

Empleados

640

EBITDA

-3.8M

57M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+80.66% upside

Dividendos

By Acuity

Próximas Ganancias

4 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

158M

2.2B

Apertura anterior

8.83

Cierre anterior

9.47

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

325 / 340 Clasificación en Healthcare

ADMA Biologics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 ago 2026, 20:02 UTC

Social Media

ADMA Biologics shares are lower amid concerns over financial practices and potential SEC scrutiny, despite claims of an internal review clearing the company.

12 ago 2026, 19:46 UTC

ADMA Biologics shares are trading lower today, despite broader market gains following a positive inflation report. The stock remains near its one-month high.

11 ago 2026, 22:56 UTC

ADMA Biologics Inc shares are lower in after-market hours following an earlier decline. The price remains above its 20-day moving average.

7 ago 2026, 19:46 UTC

Correlated Moves
News

ADMA Biologics shares are lower following a securities fraud class action lawsuit alleging false statements and undisclosed transactions, amid broader negative market sentiment.

6 ago 2026, 20:02 UTC

News

ADMA Biologics reported second-quarter net income of $37.82 million and revenue of $124.40 million, driving shares higher during Thursday's session.

5 ago 2026, 23:02 UTC

News

ADMA Biologics reported second-quarter revenue of $124.4 million, missing expectations. Shares are lower in after-market trading following the earnings release.

4 ago 2026, 19:46 UTC

News

ADMA Biologics Inc. is trading higher, buoyed by strong momentum and a decline in crude oil prices that eases inflation concerns and supports consumer spending.

3 ago 2026, 19:16 UTC

ADMA Biologics Inc shares are higher today, continuing an upward trend since Friday amid broader market optimism following recent geopolitical developments.

31 jul 2026, 20:06 UTC

News

ADMA Biologics is declining amid a class action lawsuit alleging fraudulent activities, continuing a trend of four consecutive lower sessions.

30 jul 2026, 19:39 UTC

Correlated Moves

ADMA Biologics shares are lower following a decline in first-quarter performance, reflecting broader market sentiment amid ongoing investor concerns.

29 jul 2026, 18:17 UTC

News
Correlated Moves

ADMA Biologics will report second-quarter 2026 results on August 5, contributing to today's higher share price amid steady trading.

28 jul 2026, 20:06 UTC

News

ADMA Biologics Inc. is rising amid broader biotechnology sector strength, despite ongoing legal challenges. The stock has shown steady gains since Monday's close.

27 jul 2026, 19:41 UTC

ADMA Biologics Inc shares are higher today, continuing a strong performance since Friday. No specific news was identified to explain the gains.

24 jul 2026, 19:26 UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

22 jul 2026, 18:36 UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

21 jul 2026, 19:36 UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

20 jul 2026, 19:46 UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Comparación entre iguales

Cambio de precio

ADMA Biologics Inc previsión

Precio Objetivo

By TipRanks

80.66% repunte

Estimación a 12 Meses

Media 17 USD  80.66%

Máximo 21 USD

Mínimo 12 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ADMA Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

3

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

325 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
help-icon Live chat